Apollo-backed Thoreau Group — led by former New Mountain Capital executive Matt Holt — is in advanced talks to acquire Ensemble Health Partners at a $12 billion valuation. If completed, it would rank among the largest private equity-backed healthcare services transactions in recent history.
Reported deal valuation. Ensemble manages $46B in patient revenue annually across 12,000 employees — one of the largest independent RCM operators in the country.
Bloomberg first reported that Thoreau Group is in advanced discussions to acquire Ensemble Health Partners, with sources citing a valuation of approximately $12 billion. A transaction could be finalized imminently. No final agreement has been reached and terms remain subject to change.
Ensemble's current investor base — Warburg Pincus, Berkshire Partners, and Bon Secours Mercy Health — would exit or significantly reduce their positions. Thoreau Group is expected to become the controlling shareholder. Representatives for all parties have declined to comment publicly.
Headquartered in Blue Ash, Ohio, Ensemble provides billing, payments, and end-to-end revenue cycle services to hospitals and health systems. The company manages approximately $46B in patient revenue annually and employs roughly 12,000 people — making it one of the largest and most recognized independent RCM operators in the U.S.
At $12 billion, this is a clear statement about how sophisticated investors are valuing scaled RCM operations. The RCM outsourcing market is estimated at $34 billion today and projected to roughly double by 2030, driven by rising payer complexity, workforce pressure, and the rapid adoption of AI-enabled automation. Ensemble sits directly at the intersection of all three.
Thoreau Group's interest in Ensemble reflects a conviction that scaled, technology-enabled revenue cycle services — with the data volume to train and validate AI at the enterprise level — are worth a fundamentally different multiple than traditional BPO.
What makes this deal particularly compelling is Ensemble's AI positioning. The company has been building an RCM-native large language model in partnership with Cohere — fine-tuned on real claims data from 30+ health systems. That initiative, which RevCycleAI covered in April, gives Ensemble something most RCM vendors cannot replicate quickly: a proprietary model trained on live operational data at scale.
Under Apollo's ownership, with dedicated growth capital behind it, that AI build-out becomes a core platform investment — not an R&D project on the side. The combination of Ensemble's operational depth and a purpose-built AI layer is exactly the kind of differentiation that drives enterprise contract retention and expansion.
Patient revenue managed by Ensemble annually. That volume is simultaneously the business moat and the AI training asset — and it's why this acquisition is being priced as a platform, not a services business.
Apollo Global Management's backing of Thoreau Group is significant beyond the capital it provides. Apollo brings deep healthcare services portfolio experience, operational infrastructure, and institutional relationships with the large health systems that are Ensemble's natural growth targets.
PE firms operating at this scale in healthcare services can generate organic growth through portfolio connectivity and enterprise relationships that smaller buyers cannot access. For Ensemble's hospital and health system clients, an Apollo-backed ownership structure signals long-term commitment and the resources to invest in the platform — AI, technology, and service delivery — at the level enterprise contracts require.
Apollo's involvement also reflects confidence in the regulatory environment. A technology-enabled RCM services platform with no direct clinical decision-making authority is a clean investment profile in a period of heightened healthcare PE scrutiny.
A few things to watch as this deal progresses:
This is one of the defining RCM transactions of the decade. A $12 billion valuation for an RCM operator says clearly that the market understands what Ensemble has built — not just a billing services company, but a scaled data and workflow platform with a genuine AI layer being developed on top of it.
For RCM leaders, the takeaway is straightforward: the best-capitalized, most data-rich operators are pulling ahead. Ensemble under Apollo ownership will be a more capable, more technology-forward platform than it is today. That raises the bar for every vendor competing in the enterprise health system market.
Deal analysis, vendor moves, and payor intelligence — delivered every morning before your workday starts.